Acetic Acid

Acetic Acid

SCHEMBL155186

CC(=O)O.COc1cc2ccccc2oc1=O

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.60
MEN1 O00255 1/20 0.60
MAOB P27338 8/20 0.58
KDM4E B2RXH2 4/20 0.58
CA12 O43570 2/20 0.58
CA9 Q16790 2/20 0.58
CYP1A2 P05177 2/20 0.58
NT5E P21589 1/20 0.58
HPGD P15428 4/20 0.57
ALDH1A1 P00352 4/20 0.57
NPC1 O15118 3/20 0.56
RAB9A P51151 3/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
MAPT P10636 2/20 0.56
GAA P10253 1/20 0.56
CA1 P00915 1/20 0.55
CA3 P07451 1/20 0.55
TSHR P16473 1/20 0.55
CA4 P22748 1/20 0.55
CA6 P23280 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL106241 0.92 MEN1 (0.60) KMT2AMEN1MAOBKDM4ECA12
Coumarin SCHEMBL18343641 0.92 MCL1 (0.57) KMT2AMEN1MAOBKDM4ECA12
SCHEMBL8881622 0.90 MEN1 (0.58) KMT2AMEN1MAOBKDM4ECA12
Hydrochloric Acid SCHEMBL11233384 0.90 MEN1 (0.58) KMT2AMEN1MAOBKDM4ECA12
SCHEMBL8881621 0.90 MEN1 (0.58) KMT2AMEN1MAOBKDM4ECA12
Fumaric Acid SCHEMBL27312330 0.90 KMT2A (0.56) KMT2AMEN1MAOBKDM4ECA12
Bicarbonate SCHEMBL4227922 0.84 KDM4E (0.58) KMT2AMEN1MAOBKDM4ECA12
SCHEMBL1045399 0.84 KDM4E (0.61) KMT2AMEN1MAOBKDM4ECA12
SCHEMBL28325417 0.83 SMN1; SMN2 (0.73) KMT2AMEN1MAOBKDM4ECA12
Methyl Alcohol SCHEMBL27953712 0.83 KDM4E (0.59) KMT2AMEN1MAOBKDM4ECA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116211966-A Application of plant extract, novel coronavirus main protease inhibitor and screening method 西北大学 2023-06-06 CN disclosed
US-20160257988-A1 Indicator Molecules For Use In Detecting Enzyme Cleavage Activity MOLOGIC LIMITED (GB) 2016-09-08 US disclosed
EP-3060921-A1 INDICATOR MOLECULES FOR USE IN DETECTING ENZYME CLEAVAGE ACTIVITY Mologic Limited (GB) 2016-08-31 EP disclosed
WO-2015059482-A1 INDICATOR MOLECULES FOR USE IN DETECTING ENZYME CLEAVAGE ACTIVITY MOLOGIC LIMITED (GB) 2015-04-30 WO disclosed
US-8999644-B2 Method for detecting the presence of a DNA minor contributor in a DNA mixture CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CH) 2015-04-07 US disclosed
EP-2635706-B1 METHOD FOR DETECTING THE PRESENCE OF A DNA MINOR CONTRIBUTOR IN A DNA MIXTURE CT HOSPITALIER UNIVERSITAIRE VAUDOIS (CH) 2015-04-01 EP disclosed
US-20130260380-A1 METHOD FOR DETECTING THE PRESENCE OF A DNA MINOR CONTRIBUTOR IN A DNA MIXTURE CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CH) 2013-10-03 US disclosed
EP-2635706-A1 METHOD FOR DETECTING THE PRESENCE OF A DNA MINOR CONTRIBUTOR IN A DNA MIXTURE Centre Hospitalier Universitaire Vaudois (CH) 2013-09-11 EP disclosed
US-8501426-B2 Method for identifying protease inhibitors VERTEX PHARMACEUTICAL INCORPORATED (US) 2013-08-06 US disclosed
WO-2012059888-A1 METHOD FOR DETECTING THE PRESENCE OF A DNA MINOR CONTRIBUTOR IN A DNA MIXTURE CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CH) 2012-05-10 WO disclosed
EP-1864137-A2 METHODS TO IDENTIFY AND CHARACTERIZE PROLYL OLIGO-PEPTIDASES BY USING SUBSTRATES AND PRODUCTS THEREOF DIGILAB BioVisioN GmbH (DE) 2007-12-12 EP disclosed
EP-1795606-A1 Method for screening for proteases and their substrates DIGILAB BioVisioN GmbH (DE) 2007-06-13 EP disclosed
WO-2007039184-A2 METHOD AND ANALYTICAL REAGENTS FOR IDENTIFYING THERAPEUTICS USING BIOMARKERS RESPONSIVE TO THIAZOLIDINEDIONES DIGILAB, INC. (US) 2007-04-12 WO disclosed
EP-1766416-A1 USE OF STANDARDS FOR MONITORING ALTERATIONS OF PEPTIDE AND PROTEIN SAMPLES DIGILAB BioVisioN GmbH (DE) 2007-03-28 EP disclosed
US-20070037143-A1 Method for screening for protease modulators DIGILAB BIOVISION GMBH (DE) 2007-02-15 US disclosed
WO-2007017293-A2 METHOD FOR SCREENING FOR PROTEASES AND THEIR SUBSTRATES DIGILAB BIOVISION GMBH (DE) 2007-02-15 WO disclosed
EP-1741790-A1 Methods to identify and characterize prolyl oligopeptidases by using substrates and products thereof DIGILAB BioVisioN GmbH (DE) 2007-01-10 EP disclosed
WO-2006100096-A2 METHODS TO IDENTIFY AND CHARACTERIZE PROLYL OLIGO-PEPTIDASES BY USING SUBSTRATES AND PRODUCTS THEREOF DIGILAB BIOVISION GMBH (DE) 2006-09-28 WO disclosed
EP-1619503-A1 Use of standards for monitoring alterations of peptide and protein samples BioVisioN AG (DE) 2006-01-25 EP disclosed
WO-2006005622-A1 USE OF STANDARDS FOR MONITORING ALTERATIONS OF PEPTIDE AND PROTEIN SAMPLES DIGILAB BIOVISION GMBH (DE) 2006-01-19 WO disclosed